

January 1, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir/Madam,

Sub: Information under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that Auro Pharma Limited ("Auro Pharma"), a wholly owned subsidiary of Aurobindo Pharma Limited (the "Company") at its meeting held today i.e. January 1, 2026 has approved the acquisition of non-oncology prescription formulations business (the "Business") of Khandelwal Laboratories Private Limited on a going concern basis through a Business Transfer Agreement ("BTA").

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as **Annexure A**.

This is for your information and record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Encl.: Annexure A

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure -A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

<p>a) Name of the target entity, details in brief such as size, turnover etc.;</p>	<p>i) Name of the Target Business:</p> <p>The branded non-oncology prescription formulations business of Khandelwal Laboratories Private Limited ("Khandelwal"), as a going concern, including without limitation inventory, intellectual property, employees, contracts etc. on a slump sale basis (the "Business") is being acquired by Auro Pharma Limited, a wholly owned subsidiary of the Company.</p> <p>ii) Details of the Target Business:</p> <p>Khandelwal operates in pharmaceutical industry in India in branded oncology and non-oncology prescription formulations business. Auro Pharma is acquiring the Business as a going concern. There are 23 Brands marketed in 67 SKUs and 9 pipeline products in the Business where anti-infective as well as pain management are the major portfolios.</p> <p>The Business generated a turnover of INR 1,135.3 Mn in FY2024-25 with an EBITDA of INR 289.9 Mn.</p> <p>The Business has around 470 people strong field force and has more than 1600 stockists and other distribution related infrastructure.</p>
<p>b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length".</p>	<p>The acquisition of the Business does not fall within the definition of related party transaction.</p> <p>The promoter / promoter group/ group companies do not have any interest in the Business being acquired.</p>
<p>c) Industry to which the business of the target entity being acquired belongs;</p>	<p>Pharmaceuticals industry.</p>
<p>d) Name of acquirer</p>	<p>Auro Pharma Limited, a company incorporated under the provisions of the Companies Act, 2013, bearing corporate identification number U46497TS2023PLC179262, and having its registered office at Galaxy, Floors 22-24, Plot No. 1, Survey No. 83/1, Gachibowli, Seri Lingampally, K.V. Rangareddy – 500032, Telangana.</p>

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

e) Relationship of acquirer with the listed entity	Auro Pharma Limited is a wholly owned subsidiary of Aurobindo Pharma Limited.
f) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The acquisition of the aforesaid Business shall add further brands in pain management and anti-infective which shall complement the existing product portfolios of the Company and help in expanding its business in domestic market. The acquisition will be with effect from January 1, 2026.
g) Brief details of any governmental or regulatory approvals required for the acquisition;	No approval is required.
h) Indicative time period for completion of the acquisition;	The transaction has been signed and closed on January 1, 2026.
i) Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration of INR 3,250 million subject to true up adjustments for the working capital as provided for in the definitive agreements.
e) Cost of acquisition or the price at which the shares are acquired;	Not applicable.
k) Percentage of shareholding / control acquired and / or number of shares acquired;	No control or shares of Khandelwal are proposed to be acquired and only the Business is being acquired as a going concern, on slump sale basis.
l) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	The Business is operating since 1973-74 in the Indian pharmaceutical business and sells branded non-oncology prescription formulations business and its turnover for the last three years is as follows: 2022-23: INR 1,049.8 million 2023-24: INR 1,146.9 million 2024-25: INR 1,135.3 million Country of presence of Business: India.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com